What if drug development could be faster, more efficient, and centered on what matters most to patients?
In this episode, host Elaine Hamm, PhD, sits down with Klaus Romero, MD, CEO of the Critical Path Institute (C-Path), to explore how two decades of global collaboration have reshaped the way we bring new medicines to life. From redefining clinical endpoints to accelerating treatments for complex diseases like Alzheimer’s and tuberculosis, C-Path is leading a movement to remove bottlenecks in drug development through data, regulatory science, and partnership.
In this episode, you’ll discover:
- How C-Path’s collaborative model helps de-risk and speed up the drug development process.
- Why patient-focused science is so essential for meaningful innovation.
- How data sharing, trust-building, and regulatory transparency drive real-world impact.
Tune in to learn how C-Path is bridging science, regulation, and patient need—transforming the future of drug development through collaboration.
Links:
Connect with
Klaus Romero, MD, and check out
Critical Path Institute.
Connect with
Elaine Hamm, PhD, and learn about
Tulane Medicine Business Development and the
School of Medicine.
Learn more about
Cadenza Bio and the
FDA's Critical Path Initiative.
Connect with
Ian McLachlan, BIO from the BAYOU producer.
Check out
BIO on the BAYOU and make plans to attend October 28 & 29, 2025.
Learn more about
BIO from the BAYOU - the podcast.
Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.